pyrroles has been researched along with Familial Combined Hyperlipidemia in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 23 (79.31) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alegret, M; Cofán, M; Laguna, JC; Llaverias, G; Pou, J; Ros, E; Sánchez, A; Sánchez, RM; Vázquez-Carrera, M; Zambón, D | 1 |
| Antonini, R; Arca, M; Baroni, MG; Cambuli, VM; Campagna, F; Filippi, E; Montali, A; Quagliarini, F; Romeo, S; Sentinelli, F | 1 |
| Ascaso, JF; Lorente, R; Martínez-Hervás, S; Molina, M; Navarro-Hidalgo, MI; Priego, A; Real, JT | 1 |
| Bonner Freeman, A; Brouwers, MC; Konrad, RJ; Lu, A; Schaper, NC; Stehouwer, CD; Troutt, JS; van Greevenbroek, MM | 1 |
| Anzivino, C; Baldelli, E; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Galli Kienle, M; Loria, P | 1 |
| Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D | 1 |
| Barrett, PH; Batal, R; Bernier, L; Cohn, JS; Davignon, J; Dubreuil, D; Jacques, H; Mamer, O; Rodriguez, C; Roy, M; Tremblay, M; Veilleux, L | 1 |
| Ceska, R; Malik, J; Melenovsky, V; Pisarikova, A; Poledne, R; Simek, J; Skrha, J; Stavek, P; Wichterle, D | 1 |
| Hansen, JB; Nordøy, A; Svensson, B | 1 |
| Ceska, R; Haas, T; Malik, J; Malik, M; Melenovsky, V; Simek, J; Wichterle, D | 1 |
| Castro Cabezas, M; Jansen, H; Meijssen, S; van Dijk, H; Verseyden, C | 1 |
| Dierkes, J; Güttler, K; Luley, C; Westphal, S; Wiens, L | 1 |
| Blanco-Colio, LM; Díaz, C; Egido, J; Hernández, G; Martín-Ventura, JL; Sol, JM | 1 |
| Cabezas, MC; Meijssen, S; Verseyden, C | 1 |
| Castro Cabezas, M; Erkelens, DW; Jansen, H; Meijssen, S; Verseyden, C | 1 |
| Jacobs, PL; Johnson, BM; Nash, MS | 1 |
| Bittolo Bon, G; Calabresi, L; Cattin, L; Fellin, R; Manzato, E; Montagnani, M; Pauciullo, P; Pisciotta, L; Sirtori, CR | 1 |
| Ahn, JY; Choi, IS; Chung, WJ; Han, SH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK | 1 |
| Cariolou, M; Christidis, DS; Elisaf, MS; Ganotakis, ES; Kakafika, AI; Liberopoulos, EN; Mikhailidis, DP; Miltiadous, GA | 1 |
| Antonini, R; Antonini, TM; Arca, M; Di Angelantonio, E; Diczfalusy, U; Iuliano, L; Micheletta, F; Montali, A; Natoli, S; Riggi, S | 1 |
| Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Das, S; Gidding, SS; Mitchell, D; Zhang, S | 1 |
| Avisar, I; Brook, JG; Wolfovitz, E | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 1 |
| Chik, G; Christ, ER; Crook, MA; Lumb, PJ; Semra, Y; Wierzbicki, AS | 1 |
| Brox, J; Hansen, JB; Nordøy, A; Svensson, B | 1 |
| Boquist, S; Danell-Toverud, K; Hamsten, A; Karpe, F | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Aristegui, R; Civeira, F; Díaz, C; García-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Recalde, D; Sol, JM | 1 |
19 trial(s) available for pyrroles and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols | 2012 |
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Topics: Adult; Apolipoproteins E; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Kinetics; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles; Time Factors | 2002 |
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
Topics: Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2002 |
Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Factor VIIa; Fasting; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Kinetics; Male; Middle Aged; Peptide Fragments; Postprandial Period; Prothrombin; Pyrroles; Thrombophilia; Triglycerides | 2003 |
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Topics: Adult; Atorvastatin; Autonomic Nervous System; Baroreflex; Cross-Over Studies; Fenofibrate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrroles | 2003 |
Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Chylomicrons; Complement C3; Fasting; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Postprandial Period; Pyrroles; Triglycerides | 2003 |
Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia.
Topics: Administration, Oral; Adult; Atorvastatin; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Particle Size; Postprandial Period; Probability; Prospective Studies; Pyrroles; Risk Assessment; Statistics, Nonparametric; Treatment Outcome | 2003 |
Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
Topics: Adult; Antineoplastic Agents; Atorvastatin; Bezafibrate; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Endothelial Cells; Fas Ligand Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Membrane Glycoproteins; Mevalonic Acid; Middle Aged; Pyrroles; Terpenes; Time Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha | 2004 |
Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Atorvastatin; Cholesterol; Fasting; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia.
Topics: Administration, Oral; Adult; Apolipoproteins B; Atorvastatin; Cholesterol; Fat Emulsions, Intravenous; Fats; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Particle Size; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Topics: Arteriosclerosis; Atorvastatin; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome; Ultrasonography | 2005 |
Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Topics: Adult; alpha-Tocopherol; Atorvastatin; Biomarkers; Drug Combinations; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxycholesterols; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Ketocholesterols; Lipids; Lipoproteins; Male; Middle Aged; Models, Biological; Oxidative Stress; Pyrroles | 2007 |
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography | 2007 |
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Drug Synergism; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Postprandial Period; Pyrroles; Triglycerides | 2001 |
Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipids; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Postprandial Period; Pyrroles; Sweden; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bezafibrate; Cholesterol; DNA; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Triglycerides | 2002 |
10 other study(ies) available for pyrroles and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment.
Topics: Aged; Atorvastatin; Gene Expression Profiling; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Inflammation Mediators; Male; Middle Aged; Monocytes; Pyrroles; Treatment Outcome | 2008 |
Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
Topics: Adiponectin; Adult; Age Distribution; Atorvastatin; Biomarkers; Cholesterol, HDL; Family; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Phenotype; Prevalence; Pyrroles; Randomized Controlled Trials as Topic; Waist Circumference; Young Adult | 2009 |
[Subclinical carotid atherosclerosis in patients with familial combined hyperlipidemia. Two years follow-up after treatment with high doses of atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Statistics, Nonparametric; Ultrasonography | 2012 |
Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Body Mass Index; Family Health; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Sterol Regulatory Element Binding Protein 2 | 2011 |
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Female; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxylation; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Combined hyperlipidemia in a single subject with tetraplegia: ineffective risk reduction after atorvastatin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cervical Vertebrae; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Male; Odds Ratio; Pyrroles; Spinal Cord Injuries; Treatment Failure; Triglycerides; Wounds, Gunshot | 2004 |
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Metabolic syndrome with early aortic atherosclerosis in a child.
Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Effect of atorvastatin on plasma fibrinogen.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles | 1998 |
Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Prospective Studies; Pyrroles; Rhabdomyolysis; Simvastatin; Triglycerides | 1999 |